BCOP Webinar -- CAR T cell Therapy in 2019: Evolving Treatment and Management Strategies (Cert # L199206)

ACPE Number: 0217-9999-19-123-H01-P
Release Date: 05/15/2019
Expiration Date: 11/12/2019
Activity Type: Application-based
CE Credits: 1.5 hours (BPS and ACPE)
Activity Fee: $99 (ASHP member); $159 (non-member) 

Accreditation for Pharmacists

The American College of Clinical Pharmacy and American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

 

Target Audience

This activity is intended for Board Certified Oncology Pharmacy Specialists in need of recertification credit. 

Activity Overview

This course is intended for BCOPs in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS) to provide an overview of recent standards and guidelines that specialists should be familiar with in practice. 

This online activity is approved for 1.5 hours of continuing pharmacy education credit and/or recertification credit. 

Recertification Credit*

Board certified pharmacists are eligible to receive up to 1.5 hours of recertification credit for completing this webinar. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed.  You are allowed only one attempt to successfully complete this assessment.

This webinar is not intended for those preparing to take the BPS Oncology Pharmacy Specialty Examination for Certification. To prepare for the examination, please see courses here: http://elearning.ashp.org/catalog/onc-review 

These activities are part of the ACCP and ASHP professional development program for BCACP recertification approved by the BPS.

For full program information, please visit: http://elearning.ashp.org/catalog/onc-recert 

ACPE Number

Learning Module

Credit Hours

Pass Point

0217-9999-19-123-H01-P

CAR T cell Therapy in 2019: Evolving Treatment and Management Strategies

1.50

81%

 

Learning Objectives

After participating in this CPE activity, learners should be able to:

  • Evaluate clinical trial updates supporting the use of chimeric antigen receptor (CAR) T-cells in acute lymphoblastic leukemia (ALL) and large B cell lymphoma (LBCL)
  • Apply the new consensus grading for cytokine release syndrome (CRS) and neurologic toxicity associated with immune effector cells (IEC)
  • Outline the prevention and management of toxicities associated with CAR T-cell therapy
  • Describe the structure and mechanism of CAR T-cells for refractory multiple myeloma 

Faculty

Christina Bachmeier, Pharm.D., BCOP
Clinical Pharmacist, Cellular Immunotherapy
Moffitt Cancer Center
Tampa, Florida                                                                                                        

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identify and resolve conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Christina Bachmeier serves as an advisor for Kite Pharma.
  • This activity discusses investigational products.

Methods and CE Requirements

This activity consists of audio and slides, a PDF book chapter, an attestation statement, and an activity evaluation. Learners must review all content and complete the attestation statement and evaluation to receive continuing pharmacy education credit for the activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

System Technical Requirements

Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites. 

View the minimum technical and system requirements for learning activities. 

Development

These activities were developed by ACCP and ASHP